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Han-Woong Lee,3,20 Yonghwan Kim,1,20,* and Tae-Joon Cho5,20,*
SPONASTRIME dysplasia is a rare, recessive skeletal dysplasia characterized by short stature, facial dysmorphism, and aberrant radio-
graphic findings of the spine and long bone metaphysis. No causative genetic alterations for SPONASTRIME dysplasia have yet
been determined. Using whole-exome sequencing (WES), we identified bi-allelic TONSL mutations in 10 of 13 individuals with
SPONASTRIME dysplasia. TONSL is a multi-domain scaffold protein that interacts with DNA replication and repair factors and which
plays critical roles in resistance to replication stress and the maintenance of genome integrity. We show here that cellular defects in
dermal fibroblasts from affected individuals are complemented by the expression of wild-type TONSL. In addition, in vitro cell-based as-
says and in silico analyses of TONSL structure support the pathogenicity of those TONSL variants. Intriguingly, a knock-in (KI) Tonsl
mouse model leads to embryonic lethality, implying the physiological importance of TONSL. Overall, these findings indicate that ge-
netic variants resulting in reduced function of TONSL cause SPONASTRIME dysplasia and highlight the importance of TONSL in em-
bryonic development and postnatal growth.Introduction
SPONASTRIME dysplasia (MIM: 271510), the denotation
of which originates from ‘‘spondylar and nasal alterations
with striatedmataphyses,’’1 is a very rare but distinct entity
that can be categorized as a spondyloepimetaphyseal
dysplasia that is transmitted as an autosomal-recessive
trait. To date, only 15 individuals with this disorder have
been reported1–10 on the basis of the diagnostic criteria,
suggested by Langer et al.,5 that consist of a unique combi-
nation of clinical and radiological findings. Themajor clin-
ical features aremild tomoderate short-limb type dwarfism
and a relatively large head with a prominent forehead, as
well as epicanthic folds observed in infancy or early child-
hood. However, the clinical criteria are nonspecific and
radiological features must be present for a diagnosis. Diag-
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changes in the long bones. Metaphyseal irregularities and
striations, as proposed by the disease’s name, are also
important diagnostic criteria, but they are not seen as
consistently as the lumbar vertebral changes.5 To date,
causative genetic mutations for SPONASTRIME dysplasia
have not been determined, and thus a genetic test for
this disease is not yet clinically available.
Tonsoku-like DNA repair protein (TONSL) is a multi-
domain scaffold protein that interacts with DNA replica-
tion and repair factors, including anti-silencing function
1 (ASF1), minichromosomemaintenance complex compo-
nent helicases (MCM helicases), H3 histone, H4 histone,
and MMS22-like protein (MMS22L).11–15 TONSL consists
of 1,378 amino acids, such as eight tetratricopeptide re-
peats (TPR), three Ankyrin (ANK) repeats, an ubiquitin-
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with annotated domains.13 It was reported that the
TONSL-MMS22L heterodimer plays a key role in the ho-
mologous recombination required for repairing sponta-
neous replication-associated DNA lesions. At the cellular
level, depleting TONSL causes pronounced defects in the
rate of cell proliferation and enhances sensitivity to camp-
tothecin (CPT), a topoisomerase 1 inhibitor that induces
DNA breakage at replication forks.12,13 Specifically,
TONSL-MMS22L is recruited to the sites of stalled replica-
tion forks during normal S phase by replication protein A
(RPA1, RPA2, and RPA3) bound to single-strand DNA
(ssDNA), and it promotes RAD51 loading for strand inva-
sion.16 Therefore, it was demonstrated that small inter-
fering RNA (siRNA)-mediated TONSL knockdown leads to
the loss of damage-induced RAD51-foci formation in cells
treated with genotoxic agents.11,12,16
In this study, in order to identify the causative genetic
alteration for SPONASTRIME dysplasia, we recruited 13 in-
dividuals, including one whose case had been previously
reported,10 from four different ethnicities; all of these indi-
viduals satisfied the diagnostic criteria of the disease. By
performing whole-exome sequencing (WES) and Sanger
sequencing, we identified autosomal-recessive hypomor-
phic and loss-of-function (LoF) mutations in the TONSL
(MIM: 604546) gene of individuals with SPONASTRIME
dysplasia. In further studies, using dermal fibroblasts
from affected individuals, in vitro cell-based assays, in silico
structure simulation, and an in vivo knock-in (KI) mouse
model, we demonstrated the pathogenicity of TONSL var-
iants, suggesting that defects in replication-associated
DNA-damage repair and the resultant inefficient cell prolif-
eration due to TONSL mutations might be the underlying
pathogenic mechanism for SPONASTRIME dysplasia.Material and Methods
Subjects
Written informed consent was obtained from the affected individ-
uals or their parents. The institutional review boards of the Seoul
National University Hospital, Seoul, Republic of Korea and Sam-
sung Medical Center, Seoul, Republic of Korea approved the
studies.
Whole-Exome Sequencing and Whole-Genome
Sequencing
To identify genomic variants that cause SPONASTRIME, we per-
formed WES. Additionally, whole-genome sequencing (WGS)
was conducted in cases where only a single pathogenic TONSL
allele was identified by WES (individuals P01-1 and P01-2). The
basic statistics of the WES data are summarized in Table S2. On
the basis of the inheritance pattern of the affected individuals,
we hypothesized that the disease is inherited in an autosomal-
recessive fashion. Thus, we eliminated variants that did not satisfy
the following criteria: (1) the variants showed an allele frequency
<1% in the National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project (ESP6500) and the 1000 Genomes Proj-
ect; (2) the variants were not found in our in-house database; (3)
the variants were protein-altering variants; and (4) the variants440 The American Journal of Human Genetics 104, 439–453, Marchhad a high quality of reads (read number > 20, quality score
(QS) > 30, or minor-allele frequency (MAF) > 20%). The resulting
list of variants is displayed in Table S3. For the structural variants
from WGS data, we used Manta (0.20.2) with the default settings
and Control-FREEC (6.4) for identifying copy-number variants
(CNVs) (see Web Resources). In Control-FREEC, the window size
was set as 10,000, and read counts were normalized on the basis
of GC-content bias. CNV type was classified on the basis of a
genome ploidy value of 2; values below 2 denoted loss, and values
above 2 denoted gain.
Amino Acid Conservation and Base-Level Functionality
Analyses
To evaluate the functionality of nine missense variants in TONSL,
we downloaded orthologous sequences from 61 mammalian spe-
cies from the UCSC Browser and aligned them with human
TONSL. The CADD and GERP scores across TONSL coding se-
quences were downloaded from dbNSFP.17
Long-Range PCR
We conducted long-range PCR (LR-PCR) to analyze the TONSL
exon 23 deletion found in individuals P01-1, P01-2, and their
mother by using the following primers: TONSL-exon22-F: 50-GAA
GAGACTGCCAAGCCAAG-30 and TONSL-exon24-R: 50-TACCATT
TCTGTGGCCCTTC-30.
Sanger Sequencing
The sequencing of TONSL candidate variants that were found with
WES or WGS analysis was conducted via standard PCR and Sanger
sequencing methods (primer sequences available upon request).
The sequence data were aligned to the reference sequence in Se-
quencher software (Gene Codes).
Reverse Transcription-PCR and Cloning
To investigate both the splicing changes caused by the splicing site
and deep intronic mutations in individual P11, we performed
reverse transcription-PCR (RT-PCR) and cloned the amplicon.
The proband’s and parents’ mRNA was harvested from circulating
leukocytes with the QIAamp RNA Blood Mini Kit (QIAGEN).
cDNA was transcribed with the Transcriptor First Strand cDNA
Synthesis Kit, and then PCR amplification was carried out with
the primers TONSL4F 50-TATGACCACTGCCAGTCGAG-30 and
TONSL11R 50-TGAGCTCCCGTAGTCTGGTT-30, which encom-
pass both paternal and maternal mutations. After PCR-based clon-
ing was performed with an All in One PCR Cloning Kit (Biofact),
we picked 30 colonies for PCR and sequencing analyses conducted
with the same primers.
Cell Culture, Cell Immortalization, Mutagenesis, and
TONSL Cell Line Establishment
Dermal fibroblasts from affected individuals were grown in high-
glucose and no-glutamine DMEM (GIBCO, 10313) supplemented
with 15% fetal bovine serum (FBS; GIBCO), glutamine (GIBCO,
35050-061), minimum essential medium (MEM) non-essential
amino acid (GIBCO, 11140-050), and penicillin and streptomycin
(GIBCO, 15140-122), and they were grown in 5% CO2 and 3% O2
at 37C. We used BJ foreskin fibroblasts obtained from ATCC as a
normal control. HeLa, U2OS, and 293T cells were grown in high-
glucose DMEM (GIBCO, 11965) supplemented with 10% FBS
and penicillin and streptomycin (GIBCO, 15140-122), and they
were grown in 5% CO2 at 37
C. Dermal fibroblasts from affected7, 2019
individuals were transformed by the human papilloma virus E6
and E7 (HPV16 E6E7) protein and immortalized by the catalytic
subunit of human telomerase (hTERT) through retroviral trans-
duction. HPV16 E6E7 genes (a gift from Howley Lab, Harvard
Medical School) were subcloned into pMSCVneo (Clontech) and
used for transforming the dermal fibroblasts. pWZL-hTERT was
used to immortalize the dermal fibroblasts from the affected indi-
viduals. The gene-coding wild-type (WT) TONSL was amplified
from a cDNA library prepared from U2OS cells by PCR with the
following primers: TONSL-F (50-GGGGACAAGTTTGTACAAAAA
AGCAGGCTTAATGAGCCTGGAGCGCGAGC-30) and TONSL-R
(50-GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAGAGGCGC
CGAAAGAAGAGC-30). The PCR product was cloned into a
Gateway BP vector, pDONR223, with BP clonase. The pDONR223
clone was sequenced and then recombined into pHAGE vectors
with LR clonase (Thermo Fisher Scientific). Using the
pDONR223-TONSL template, we generated the point mutation
plasmids used in this study with the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Genomics). The primers we
used to generate TONSL mutations are listed in Table S5.Fiber Analysis
For replication-fork stalling, cells from individual P03 were pulse-
labeled with 25 mM 5-chloro-20-deoxyuridine (CldU: Sigma-
Aldrich C6891), washed with PBS, pulse-labeled with 250 mM
5-iodo-20-deoxyuridine (IdU; Sigma-Aldrich I7125), and har-
vested. The cells were washed and resuspended to 53 105 cells/mL
in PBS. The cells were lysed in spreading buffer (200 mM Tris-HCl
[pH 7.5], 50 mM EDTA, 0.5% SDS) on glass slides. The DNA fibers
were spread by gravity, then fixed with methanol:acetic acid (3:1)
denatured with 2.5M HCl. CldU was detected with rat anti-BrdU
antibody (clone BU1/75, ICR1; Abcam, ab6326; 1:750) and IdU
with mouse anti-BrdU antibody (clone B44; BD Biosciences,
347583; 1:750). Slides were fixed with 4% paraformaldehyde,
then stained with Alexa Fluor 594- or 488-conjugated secondary
antibodies (Life Technologies). Images were acquired with a Nikon
Eclipse Ni microscope with 603 oil-immersion objectives and NIS-
Elements software (Nikon Instruments). Replication fork struc-
tures (>1000 fork structures) and CldU/IdU track lengths (>300
ongoing forks) were analyzed in ImageJ software (US National In-
stitutes of Health [NIH]). For CPT treatment (DNA damage repair)
fiber analysis, cells were treated with 100 mM CldU for 30 min,
then 250 mM 5-iodo-20-deoxyuridine (IdU; Sigma-Aldrich I7125)
for 30 min with 2.5 mM/50 nM CPT or DMSO. We prepared a
DNA plug with by 2 3 105 to 4.5 3 105 cells/plug by using
low-melting agarose (Bio-Rad 161-3112), followed by lysis with
20 mg/mL Proteinase K (Roche 03115828001) for two days at
50C. For the stretching of DNA fibers, 22 mm 3 22 mm silanized
coverslips (Genomic Vision) were dipped into the DNA solution
for 13 min and pulled out at a constant speed (300 mM/s) with a
Molecular Combing System (Genomic Vision MCS-001). The cov-
erslips were baked for 4 h at 60C and incubated with acid for
denaturation. For detection of CldU- and IdU-labeled, the cover-
slips were incubated for 2 h at room temperature (RT) with rat
anti-BrdU antibody (dilution 1:100 detects BrdU andCldU; Abcam
6326) and mouse anti-BrdU antibody (1:10, detects BrdU and IdU;
Becton Dickinson 347580). The slides were fixed in 4% parafor-
maldehyde in PBS and incubated for 1 h at RT with Alexa Fluor
488-conjugated goat anti-rat antibody (dilution 1:100, A21208;
Molecular Probes/Thermo Fisher) or Alexa Fluor 568-conjugated
goat anti-mouse antibody (dilution 1:100, A21124; MolecularThe AmeriProbes/Thermo Fisher). Finally, they were mounted with ProLong
Gold Antifade Reagent (Molecular Probes) and stored at 20C.
DNA fibers were observed with Carl Zeiss Axio Observer 7 and
ApoTome 2 (motorized fluorescence microscope with grid projec-
tion) 63 objective lenses. For each experiment, a total of 200 DNA
fibers were analyzed; the number of DNA fibers wasmeasured with
ImageJ.
siRNA Transfection, Cell Proliferation, and CPT
Sensitivity Assay
The siRNA targeting TONSL coding regions are listed in Table S6.
Here, 3 3 105 cells were plated in six-well plates and transfected
with siRNA in reverse transfection manner. The cells were trans-
fected a second time after 24 h. Then, 48 h after the second
transfection, 4,000 cells were plated in four wells (12-well plates,
SPL) for cell counting, and 1,000 cells were plated in four wells
(96-well plates, Corning #3603) for Hoechst staining. The cells
in the 12-well plates were counted with a Z1 Coulter Particle
Counter (Beckman Coulter), and the nuclei of the Hoechst-
stained cells in the 96-well plates were counted with Cytation
3 (BioTek). Then, 1,000 cells were plated in four wells in
96-well plates and were treated 24 h after plating with increasing
concentrations of CPT. The cells were counted 5 days after
treatment. The cells were then stained with Hoechst and
counted with Gen 5 (BioTek). For cell lines from affected
individuals, 40,000 cells/well were plated in six-well plates. After
24 h, cells were treated in triplicate with increasing concentra-
tions of CPT (0–32 nM). 4 days after drug treatment, the cells
were passed 1:4 to six-well plates; then they were counted
4 days later with a Z1 Coulter Particle Counter (Beckman
Coulter).18
Immunoblot
We prepared cell lysate by boiling cells for 5 min in 23 SDS sample
buffer (RBC) at 95C. We used 7.5% precast gels (Bio-Rad) for the
resolution of the proteins. Immunoblotting was performed with
anti-HA (Biolegend; MMS-101R, Lot B224726), anti-TONSL
(Bethyl: A303-843A, Lot #1), anti-GAPDH (Santa Cruz: SC-
25778, Lot K0615), anti-phosphorylated checkpoint kinase 1
(CHK1) (Cell Signaling: 2348P, Lot #11), anti-phosphorylated
checkpoint kinase 2 (CHK2) (Cell Signaling: 2661P, Lot #11),
and anti-a-Tubulin (Abfrontier: LF-PA0146, Lot MJL01-02) anti-
bodies to detect each protein.
Immunofluorescence (BrdU/Rad51)
For immunofluorescence, 3 3 105 cells were plated in six-well
plates (SPL) with cover glass. For HeLa and U2OS cells, siRNA
was treated in a reverse and forward transfection manner and
plated 48 h after the second transfection. For BrdU incorporation,
24 h after plating, the cells were treated with BrdU (20 mg/mL) for 4
h, then fixed with 3.7% formaldehyde in PBS. The Invitrogen pro-
tocol was followed. Cells were washed in PBS and fixed in 3.7%
formaldehyde in PBS for 15 min. After being washed in PBS, the
cells were permeabilized in 0.1% Triton X-100 buffer for 20 min,
then in 1N HCl for 10 min on ice. The cells were then incubated
in 2N HCl for 10 min at RT, then in phosphate citric acid buffer
for 10 min. Cells were washed in permeabilization buffer twice,
then incubated with Alexa-Fluor-488-conjugated anti-BrdU pri-
mary antibody overnight at RT. For Rad51 and g-H2A.X immuno-
fluorescence, 24 h after plating, the cells were treated with CPT
(500 mM) overnight, then fixed in 3.7% formaldehyde forcan Journal of Human Genetics 104, 439–453, March 7, 2019 441
15 min, then permeabilized with 0.1% Triton X-100 for 20 min
with PBS washing in between. After being washed with PBS twice,
the cells were blocked with PBG (0.2% [w/v] cold fish gelatin, 0.5%
BSA in PBS) for 1 h at RT. Then, the cells were incubated in PBG
overnight at 4C with 1:7000 of anti-Rad51 antibody (Abcam,
ab133534, Lot #: GR219215-36) and 1:1000 anti-g-H2A.X anti-
body (Cell Signaling, #9718S, Lot #13). The following day, the cells
were washed three times with PBG and incubated with fluores-
cent-conjugated secondary antibody for 30 min. Secondary anti-
bodies were purchased from Abcam (Ms Alexa Fluor 594:
ab150112; Rb Alexa Fluor 594: ab150064; Ms Alexa Fluor 488:
ab150109; and Rb Alexa Fluor 488: ab150061). After being washed
with PBG three times, the coverslips were embedded in Vecta-
shield (Vector Laboratories) supplemented with DAPI. Imaging
was performed with a Nikon A1 confocal microscope equipped
with a CFI-Apochromat 603 NA-1.4 oil objective lens, the A1-
DUG GaAsP multi detector unit, and the NIS-Element C-ER soft-
ware. For the BrdU assay, the ratio was calculated by dividing the
number of BrdU-incorporated cells by the number of total cells
counted.Animals and Ethics Statement
All mice were purchased from Taconic Biosciences (Dae Han Bio-
link) and housed at the specific pathogen-free (SPF) facility of
the Yonsei Laboratory Animal Research Center. Animal experi-
mental procedures were conducted in accordance with the
Korean Food and Drug Administration (KFDA) guidelines, re-
viewed, and approved by the institutional animal care and use
committees (IACUC) at Yonsei University (Permit Number:
201506-322-02).Preparation of CRISPR-Cas9 mRNA and Donor DNA
Cas9 mRNA was synthesized with a mMESSAGE mMACHINE
T7 Ultra kit (Ambion) and diluted to working concentration in
endonuclease-free injection buffer (0.25 mM EDTA, 10 mM Tris
[pH 7.4]) immediately before microinjection. A plasmid encoding
the S. pyogenes Cas9 (SpCas9) protein19 was obtained from
ToolGen. The crRNAs were designed by searching for ‘‘NGG’’ or
‘‘CCN’’ (the reverse complement sequence of NGG) sequences
near the point mutation target sites. The crRNA sequences used
in this study were as follows: crRNA1 50-GGTCCAGCCCCCTCC
CATCC-30, crRNA2 50-GAACCCGGATGGGAGGGGGC-30, crRNA3
50-CCGGGTTCGAGTTCAAATTC-30, and crRNA4 50-CCTGAATTT
GAACTCGAACC-30. The 106 bp synthesized single-stranded
oligonucleotide (ssDNA) we used as donor DNA was c.T2770C
(p.Arg924Trp) ssDNA 50-TAGAAACTTCTGTCTTCTGACTGTCCCC
TCCCTCTGTCTTTCCTGCTAGCTTCTGGTCCAGCCTCCTCCTA
TCTGGGTTCGGGTTCAGATTCAGGATAACCTTTTCCTCATCCC
CGTTCCC-30. The tracrRNA, the crRNAs targeting the Tonsl gene,
and the ssDNA donor for homology-directed repair were obtained
from Integrated DNA Technologies (IDT).Microinjection
Microinjection of one-cell embryos was performed as previously
described.20 In brief, 3–4-week-old C57BL/6 female mice were
superovulated by intra-peritoneal (i.p.) injections of 5 IU pregnant
mare serum gonadotropin (PMSG, Sigma) and 5 IU human chori-
onic gonadotropin (hCG, Sigma) at 48 h intervals. The superovu-
lated females were then crossed with stud males, and the fertilized
eggs were collected and microinjected with a mixture of Cas9
mRNA (50 or 100 ng/mL), four crRNAs (10, 25, or 50 ng/mL442 The American Journal of Human Genetics 104, 439–453, Marcheach), tracrRNA (tracrRNA mixed with crRNA at 1:1 molar ratio),
and donor ssDNA (200 ng/mL). The microinjections were per-
formed in the cytoplasm of one-cell embryos with a piezo-driven
manipulator (Prime Tech) and followed by embryo transfer into
the oviducts of pseudo-pregnant ICR mice to produce a living
mouse.
Founder Screening and Genotyping PCR
To screen founders carrying the p.Arg924Trpmutation in the Tonsl
gene, we performed a PAGE-PCR) assay as previously described21
with genomic DNA obtained from newborns that were produced
from the microinjected embryos. In brief, the genomic regions
spanning the crRNA target site were amplified by PCR. After sim-
ply denaturing and annealing the PCR products, we analyzed
the resulting products via acrylamide gel electrophoresis. Then,
the candidates were cloned in T-Blunt PCR Cloning Vector
(SolGent) and were validated by direct sequencing analysis
(Cosmobiotech). The primer sequences we used in PAGE-PCR
were as follows: forward, 50-TGAATGCAGAGCCTGCAGAGA-30
and reverse, 50-TCTAGGGAGCAGAGTGCCAAG-30. For genotyp-
ing PCR, DNA was extracted from tails or yolk sacs. We used the
forward primer 50-AAGCAGTCTTCAGCATGGGACT-30 and the
reverse WT primer 50-AACTCGAACCCGGATG-30 to identify
the Tonsl WT allele. We used forward primer 5’-AAGCAGTCTT
CAGCATGGGACT-3’ and reverse KI primer 50-ACCCAGATAG
GAGGAG-30 to identify the Tonsl p.Arg924Trp allele. The reverse
WT primer is annealed specifically to the sequence of the Tonsl
WT allele, whereas the reverse KI primer is annealed to the
sequence of the Tonsl p.Arg924Trp allele.
Embryo Collection
Gestation was dated by the detection of a vaginal plug (as E0.5), or
after in-vitro fertilization (IVF) and embryo transfer. The embryos
were either fixed in 10%neutral buffered formalin (Sigma-Aldrich)
or snap-frozen in liquid nitrogen. Stereomicroscope images were
generated from specimens of fixed embryos.Results
Diagnosis and the Clinical Information of Individuals
with SPONASTRIME Dysplasia
We recruited 13 individuals, including one whose case had
previously been reported,10 satisfying the diagnostic
criteria of the disease from four different ethnicities—
Korean, Indian, Finnish, and Brazilian (African black and
non-Latin European). Their clinical features are presented
in Table 1 and in the Supplemental Case Reports. The me-
dian height standard deviation score (SDS) for the individ-
uals in this study was 4.9; the SDS ranged from 0.9
to 10.0, showing a wide range from mild to severe short
stature. All the recruited individuals shared similar facial
dysmorphism (Figure 1A). Other clinical findings shared
by more than one individual included a short dental
root, airway narrowing, cataracts, and joint laxity. Radio-
graphic features were characterized by distinct changes
in the vertebrae and the metaphyses of the long bones.
It is worth noting that the radiographic features changed
and became more conspicuous with age (Figure 1B and
Table S1).7, 2019
Table 1. Clinical Features of Individuals in This Series
ID P01-1a P01-2a P02 P03 P04 P05 P06 P07b P08 P09 P10 P11 P12
Ethnicity Korean Korean Korean Korean Brazilian
(African black
and non-Latin
European)
Korean Finnish Korean Indian Indian Indian Korean Indian
Age of Initial
Presentation
8 years,
5 months
6 years 2 months 13 years 2 years,
2 months
2 years,
7 months
newborn 36 years 13 years 14 years 11 years 3 years,
5 months
1 year,
9 months
Gender f m m m m f f m m f f f f
Consanguinity no no no no yes no no no no no no no no
Initial
Presentation
short
stature
short
stature
short stature radiographic
abnormality
of the knee
short stature short stature short stature neck and
shoulder
pain
short
stature
short
stature
short
stature
and limb
deformity
short stature short stature
Height at First
Measurement
(cm) (SDS)
104.1
(3.6)
93.4
(4.7)
47.9 (4.9) 145.2 (0.9) 76 (4.0) 74 (4.5) 40 (5.6) 136 (6.2) 120 (4) 119 (7) 93 (10) 73.6 (5.6) 53 (10)
Age at Latest
Measurement
17 years,
5 months
15 years 5 years,
7 months
N/A 13 years 6 years 12 years,
6 months
37 years 13 years 14 years 11 years 4 years,
2 months
2 years
Latest Height
(cm) (SDS)
124.4
(6.8)
143.5
(4.8)
82.6 (6.0) 122 (4.6) 98.8 (3.4) 85.8 (10.4) 136 (6.2) 120 (4) 119 (7) 93 (10) 80.6 (5.8)
Facial
Dysmorphism
(þ) (þ) (þ) (þ) (þ) (þ) (þ) (þ) (þ) (þ) (þ) (þ) (þ)
Cognitive
Impairment
() () () () borderline () () () () () () () ()
Other
Findings
short
dental
roots
short
dental
roots
hypothyroidism;
nystagmus;
hypospadias;
airway narrowingc
recurrent
pneumonia
in the 1st year;
short dental
roots
hypothyroidism;
recurrent pneumonia
until age 5 years;
precocious puberty
cataracts;
cerebro-vascular
aneurysm rupture;
weak voice
Arnold-Chiari
malformation;
cataracts
N/A N/A joint laxity joint laxity; hip
subluxation;
airway
narrowingc
Abbreviations are as follows: m ¼ male, f ¼ female, SDS ¼ standard deviation score, and N/A ¼ not available.
aThese two individuals are siblings.
bPreviously reported (Jeong et al.10).
cAirway narrowing was composed of glottic narrowing and diffuse tracheal narrowing.
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Figure 1. Characteristic Facial Appearance and Radiographic Findings of Individuals with SPONASTSRIME Dysplasia
(A) Facial photos of individuals from three different ethnicities. They share midfacial hypoplasia, a depressed nasal root, a short and up-
turned nose, prognathism, and a relatively large head size with a prominent forehead. Individual P05 is shown at age 5 years, individual
P06 at age 5 years, and individual P08 at age 13 years.
(B) A lateral spine view of individual P02 at age 3 years and 8 months shows a taller anterior vertebral body and convex anterior end-
plates. A lateral spine view of individual P01-2 at age 13 years shows biconcavity of the endplates. Hip and knee anteroposterior views
of individual P02 show metaphyseal irregularity and vertical striation and small, dysplastic epiphyses. Hip and knee anteroposterior
views of individual P01-2 show residual avascular necrosis of the left femoral head and mixed dense striations and lucent area at the
metaphysis of the knee.Identification of TONSL Mutations in Individuals with
SPONASTRIME Dysplasia
To identify the pathogenic mutation causing the disease,
we conducted WES of eight affected individuals and avail-
able family members from seven families (five Koreans,
one Brazilian, and one Finnish; individuals P01-1 to
P07) (Tables S2 and S3). On the basis of the hypothesis
that this disease is inherited in an autosomal-recessive
manner, we retrieved rare variants (<1% frequency in
the public databases) that were specifically harbored by
the probands among the eight individuals with homozy-
gous or compound-heterozygous status. Among the indi-
vidual-specific variants that followed a recessive pattern,
variants in TONSL were present in four individuals
(Table 2). The remaining four individuals harbored single
variants in the gene and required further analysis so that
we could verify whether they also fit into the recessive
model. For example, subsequent WGS analysis of the sib-
ling probands (individuals P01-1 and P01-2) identified an
exon 23 deletion in the maternal allele; this deletion was
validated by PCR. Next, an additional cohort from India
was recruited and subjected to singleton WES (individuals
P08 to P10), which led to the discovery of bi-allelic vari-444 The American Journal of Human Genetics 104, 439–453, Marchants in TONSL. Finally, we screened two additional
individuals (one Korean and one Indian) for such TONSL
variants by Sanger sequencing and identified bi-allelic
mutations in one (individual P11) and a single mutation
in the other (individual P12). Individual P11 has a
splicing site variant and a deep intronic variant whose
subsequent changes in mRNA were confirmed by RT-
PCR. Only one mutation was identified in the TONSL
gene in the three probands P05, P06, and P12 (Table 2).
Because the parents who were harboring the same muta-
tion were unaffected, it is highly likely that the affected
individuals had undetermined variants, such as a cryptic
structural variation or a noncoding variation, in the re-
maining TONSL allele. All the TONSLmutations identified
were confirmed by Sanger sequencing (Figures S1A and
S1B). No significant variation was found in other skel-
etal-dysplasia-related genes in affected individuals. Ten
out of thirteen affected individuals (76.9%) carried one
LoF allele and one missense allele (Table 2). Except for
nonsense mutations, which might lead to nonsense-medi-
ated mRNA decay, TONSL missense mutations were
found in various locations throughout the protein-coding
region (Figure 2A), mostly within functionally annotated7, 2019
Table 2. TONSL Mutations and Their Predicted Protein Changes Identified in 13 Individuals
ID Mutation 1 Mutation 2 Genetic Study
P01-1a exon 23 deletionb c.2800C>T p.Arg934Trp quad WES
P01-2a exon 23 deletionb c.2800C>T p.Arg934Trp quad WES
P02 c.1531C>T p.Gln511* c.2917G>A p.Gly973Arg trio WES
P03 c.735C>G / c.737delTc p.Cys245Trpfs*20 c.1615G>A p.Glu539Lys trio WES
P04 c.1673G>A p.Arg558Gln c.1673G>A p.Arg558Gln trio WES
P05 c.1090G>C p.Asp364His not identified not identified quad WES
P06 c.578þ1G>T N/A not identified not identified trio WES
P07g c.2907C>A p.Tyr969* c.3862G>C p.Glu1288Gln singleton WES
P08 c.1471_1472delTC p.Ser491Argfs*65 c.521G>A p.Ser174Asn singleton WES
P09 c.1459G>A /
c.1989_1991deld
p.Glu487Lys /
p.664delLeu
c.125G>A p.Arg42His singleton WES
P10 c.295delT p.Ser99fs*59 c.1459G>A p.Glu487Lys singleton WES
P11 c.578þ1G>A p.Thr151Argfs*42e c.1291–11_1291–
14delCCTC
p.Arg431Profs*6 /
p.431_441delf
Sanger sequencing
P12 c.1459G>A p.Glu487Lys not identified not identified Sanger sequencing
Abbreviations are as follows: WES ¼ whole-exome sequencing.
aThese two individuals are siblings.
bg.145657122_145658684del.
cPaternal allele harbors a substitution followed by a deletion of one nucleotide.
dPaternal allele harbors a substitution and an in-frame deletion.
eRT-PCR revealed an mRNA sequence change, predicting a truncated protein or nonsense-mediated mRNA decay.
fRT-PCR and cloning its products revealed WT (14/25) and two different mutant mRNAs formed by retention of a part of intron 10 (5/25) and by skipping of a part
of exon 11 (6/25); these alterations predicted these two different polypeptides.
gP07 had two mutations that were confirmed to be bi-allelic by testing his siblings because his parents had already passed away. All other individuals with two or
three mutations were confirmed to be bi-allelic by testing their parents.domains (8 out of 9). The nine missense variants dis-
played complete or near-complete evolutionary conserva-
tion across vertebrate species (Figure 2B) and were found
in low frequency in the healthy population (5/9 were
not found in the ExAC database; all nine < 1.0 3 104).
To predict the functionality of the missense variants, the
CADD and GERP scores were compared with the rest of
the amino acid residues of the protein, and they displayed
significant differences (Figures 2C and S2A–2D). TONSL is
tolerant to LoF variants (ExAC pLI ¼ 0.00), but no individ-
ual in this study carried LoF variants in both alleles,
implying a critical but minimal requirement of TONSL
function for survival.
Complementation of Defects in Dermal Fibroblasts from
Individuals by Expression of Wild-Type TONSL
In an attempt to validate that TONSL variants are causal
for the SPONASTRIME phenotype, we established primary
dermal fibroblast lines from two individuals, P03 and P04.
Immunoblot analysis showed a pronounced decrease in
TONSL levels compared to those in normal human fibro-
blasts (BJ cells) (Figure 3A). siRNA treatment abrogated
endogenous TONSL protein levels (Figures 3A and S5A).
To further validate the causative nature of TONSL vari-
ants, we transduced an empty vector (EV) and HA-tagged
WT TONSL into P03 and P04 cells (Figure 3B) and per-
formed functional complementation assays. Expressing
WT-TONSL successfully rescued the cells’ enhanced sensi-The Ameritivity to CPT (Figure 3C) and the DNA-damage-induced
RAD51-foci formation in both cell lines (Figures 3D and
3E). As controls for the CPT sensitivity assay, we used BJ
cells and FANCP cells (also known as SLX4), which are
SLX4-deficient dermal fibroblasts that were, in this case,
derived from an individual with Fanconi anemia. The
FANCP cells were found to be sensitive to CPT; this sensi-
tivity was rescued by introducing WT SLX4 protein
through lentiviral transduction.18,22 The CPT sensitivity
assays of P03 and P04 cells were designed similarly to
that of the previous FANCP cell assay, but they included
EV and WT TONSL-complemented cells. In addition to
the normal control BJ cells, we used EV and WT SLX4
FANCP cells for comparing CPT sensitivity. Also, to
confirm the impaired DNA replication caused by the
TONSL variants found in affected individuals, a BrdU-
incorporation assay was performed and quantified by
immunofluorescence. As expected, the BrdU incorpora-
tion ratios in P03/EV and P04/EV cells were less than
that in BJ cells, whereas the complemented cells showed
increased BrdU incorporation (Figure 3F). In a study by
Duro et al., it was reported that although TONSL knock-
down cells are sensitive to CPT, they are not sensitive to
hydroxyurea (HU) compared to control cells.6 In order
to test whether the fibroblasts from individuals with
mutant TONSL display similar characteristics, we treated
P03 and P04 cells with HU. Consistent with previous re-
ports, neither P03 nor P04 cells were sensitive to HUcan Journal of Human Genetics 104, 439–453, March 7, 2019 445
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Figure 2. TONSL Variants Identified in Individuals with SPONASTRIME Dysplasia
(A) Pathogenic variants in TONSL found in SPONASTRIME-affected individuals are displayed on the TONSL protein, whose known func-
tional domains are indicated. Variants in red were analyzed for variant functionality.
(B) Evolutionary conservation of the nine missense variants found in SPONASTRIME-affected individuals.
(C) Because they are parameters of an individual’s missense-variant (‘‘Pathogenic’’) functionality, CADD and GERP values were plotted,
along with residues that overlapped with the ExAC Database (‘‘ExAC’’) and residues that were not polymorphic (‘‘Other residues’’).(Figure S3). As mentioned earlier, TONSL is involved in
homologous recombination, and its impairment results
in decreased cell proliferation and increased sensitivity
to CPT.12,13 Because homologous recombination is an
important part of DNA damage repair, and thus DNA
replication, it is possible that TONSL variants might in-446 The American Journal of Human Genetics 104, 439–453, Marchcrease the occurrence of stalled replication forks as a result
of defects in DNA damage repair. In order to evaluate the
mutant TONSL’s impairment of replication restart and
DNA damage repair, we performed fiber analysis with fi-
broblasts from individual P03 and with normal control
cells (Figure S4). We used the nucleotide analogs CldU7, 2019
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Figure 3. Complementation of Dermal Fibroblasts from Individuals P03 and P04 through TONSL cDNA Transduction
(A) TONSL protein levels and corresponding siRNA-mediated TONSL depletion of cells from individuals with SPONASTRIME dysplasia.
BJ cells were used as a normal control. The basal TONSL level in cells derived from the affected individuals was lower than that in BJ cells,
and all of the cells were successfully depleted by siRNA treatment. C ¼ siControl and T ¼ siTONSL.
(B) Stable protein level of wild-type (WT) TONSL delivered through lentiviral transduction into fibroblasts derived from both individuals
P03 and P04. EV and WT denote the empty vector and wild-type, respectively. The asterisk indicates the cross-reacting band.
(C) Cells from affected individuals were sensitive to CPT but were rescued to a level comparable to that of BJ cells by the transduction of
WT TONSL. The indicated cells, in triplicate, were exposed to different concentrations of CPT ranging from 0–32 nM. After 5 days, the
cells were counted with a coulter counter, and the total number of cells at each concentration was divided by the number of untreated
(legend continued on next page)
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and IdU to track the newly synthesized DNA from the first
label origin and the second label origin, respectively.
Ongoing forks have both CldU and IdU tracks, whereas
stalled forks can be monitored by CldU-only labeled
tracks. To compare the changes in ongoing or stalled repli-
cation forks, we calculated the percentage of CldU and
IdU tracks from the total of all CldU-incorporated tracks.
Compared to in a normal human fibroblast, the percent-
age of ongoing replication forks was slightly decreased
in P03 cells, and the number of stalled forks was signifi-
cantly (Figure S4). Next, we performed fiber analysis for
CPT sensitivity in P03 and P04 cells and we used EV,
WT-TONSL, and BJ cells as controls. When treated with
50 nM of CPT, P03/EV and P04/EV cells showed decreases
in replication length compared to that in BJ cells; these
decreases were rescued by WT-TONSL (Figure 3G). Taken
together, these data provide strong evidence that the
TONSL variants found in affected individuals impair
DNA replication and repair capacity; these impairments
were all rescued by WT-TONSL, thus demonstrating the
pathogenic nature of TONSL mutations in the disease
phenotype.
Validation of Pathogenic TONSL Mutations in In Vitro
Cell-Based Assay
To systematically evaluate the pathogenicity of TONSL
variants found in other individuals whose primary fibro-
blasts were not available, we established an in vitro cell-
based assay using HeLa cell lines. We focused on missense
TONSL mutations because nonsense mutations might be
subject to nonsense-mediated mRNA decay. First, we
tested whether we could recapitulate the results of previ-
ous reports showing that TONSL depletion leads to
enhanced sensitivity to CPT.11,12 In order to accomplish
this, we established an assay system in which mutant
TONSL is expressed in a HeLa cell line, but the endoge-
nous WT is selectively knocked down. The strategy was
to establish via lentiviral transduction individual HeLa
cell lines that stably express each mutant TONSL variant,
then treat the cells with siRNA targeting the TONSL 30 un-
translated region (UTR); this process selectively knocks
down only the endogenous TONSL mRNA. If successful,
the HA-tagged TONSL is expressed, and any cellular de-cells. FANCP/EV, a Fanconi anemia-derived cell line lacking Slx4, an
mented cells, were used as controls. The error bars represent the stan
(D) Representative images of CPT-induced DNA damage in Rad51
WT-TONSL cells were treated with CPT (50 nM) overnight, then fi
Impaired DNA damage induced RAD51 foci formation in those cells f
cells via the transduction of WT-TONSL.
(E) Statistical analysis of Rad51 foci. The percentage of Rad51 foci was
divided by the total number of nuclei from non-treated cells, or, for C
The error bars represent the SD.
(F) BrdU incorporation into DNA was reduced in P03/EV and P04/EV
WT-TONSL. The BrdU incorporation ratio was calculated by dividing
counted. The error bars represent the SD of three replicates.
(G) DNA fiber analysis of CPT-treated cell lines derived from SPONAS
matic representation of the experiment is shown on the top, and the r
median value; ** p ¼ 0.003 and *** p < 0.001.
448 The American Journal of Human Genetics 104, 439–453, Marchfects arising from TONSL mutation can be observed
without the interference of the endogenous TONSL. WT-
TONSL and EV cell lines were established as positive
and negative controls, respectively. To first test the
siRNAs, we treated HeLa cells with siRNA targeting the
coding region and the 30 UTR. As shown in Figures S5A
and S5B, depleting TONSL by targeting the coding or
the 30 UTR region in HeLa cells resulted in hypersensitiv-
ity to CPT. Then, HeLa cells that stably expressed the in-
dividual EV, HA-tagged WT-TONSL, and the HA-tagged
TONSL missense mutation were successfully established
(Figure S5C). The siRNA targeting the TONSL 30 UTR selec-
tively knocked down endogenous TONSL, but not HA-
tagged WT or mutant TONSL (Figure 4A). After confirming
the selective knockdown of endogenous TONSL and
decreased TONSL protein levels, we treated EV, WT-
TONSL, and TONSL variant cells with siRNA targeting
the TONSL 30 UTR, then grew the cells for 5 days to
monitor cell proliferation. Overall, a noticeable
proliferation defect was observed in TONSL-variant
HeLa cells compared to WT-TONSL cells (Figure 4B).
Of these, proliferation of cells with the P02
c.2917G>A, (p.Gly973Arg), P01-1 and P01-2 c.2800C>T
(p.Arg934Trp), P05 c.1090G>C (p.Asp364His), and P08
c.521G>A (p.Ser174Asn) variants were significantly in-
hibited to a similar level as that of siTONSL-treated
HeLa-EV cells (Figure 4B). This result shows that all exam-
ined TONSL variants directly impact cell proliferation, but
to varying degrees. At the same time, we evaluated phos-
phorylated CHK1 and CHK2 after endogenous TONSL
depletion in the individual TONSL-variant HeLa cells.
We found that the checkpoint is activated in cells with
proliferation defects (Figure 4C), suggesting that the func-
tional impairment of TONSL leads to genome instability,
which results in cell-cycle arrest and inhibition of cell di-
vision. To further investigate the role of each TONSL
variant in repairing replication-associated DNA damage,
we performed a CPT sensitivity assay. Consistent with
the proliferation results, the CPT sensitivity of the TONSL
variant cells was comparable to that of siTONSL-treated
HeLa-EV cells, which lack TONSL (Figure 4D). In addition,
we modeled the WT and TONSL variants on the basis of
the existing available structure to determine the basis ofd FANCP/WT-SLX4, a genetically isogenic line of SLX4-comple-
dard deviation (SD) of three replicates.
and gH2A.X foci. P03/EV, P03/WT-TONSL, P04/EV, and P04/
xed and stained with anti-RAD51 and anti-gH2A.X antibodies.
rom affected individuals that were recovered to the level of normal
calculated by taking the number of nuclei with nR 10 Rad51 foci
PT-treated cells, divided by the number of gH2A.X-positive nuclei.
cells, which were rescued to a normal level by the transduction of
the number of BrdU-incorporated cells by the number of total cells
TRIME-affected individuals. BJ cells were used as a control. A sche-
epresentative DNA fiber is shown on bottom. The red line indicates
7, 2019
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Figure 4. In Vitro Cell-Based Assay of TONSL Variants Shows Defects in Cell Proliferation and Enhanced Sensitivity to Camptothecin
(A) The protein levels of recombinant WT and TONSL variants from affected individuals transduced and stably expressed in HeLa cells
upon endogenous TONSL depletion via siRNA that targeted the TONSL 30 UTR. The TONSL antibody is able to detect both endogenous
and HA-tagged TONSL, whereas the HA antibody is not able to detect endogenous TONSL. The asterisk indicates the cross-reacting band.
(B) Cell-proliferation assay showing the varied proliferation rates of cells expressing mutant TONSL. EV cells were treated with either
non-targeting siCtrl or siTONSL targeting the 30 UTR. The rest of the cells were treated with siTONSL targeting the 30 UTR. The cell pro-
liferation rate was normalized to the cell number on day 1. The error bar represents the SD of three replicates. siCtrl ¼ siControl.
(C) TONSL variants in the absence of endogenous TONSL lead to checkpoint activation. Whole-cell extracts of HeLa cells expressing
mutant TONSL were treated with siRNA targeting the 30 UTR and analyzed by immunoblot with DNA-damage-response factors, phos-
phorylated CHK1 (pCHK1), or phosphorylated CHK2 (pCHK2).
(D) TONSL variant cell lines were treated with 30 UTR-targeting siRNA as in (B), then treated with increasing concentrations of CPT. The
cells were stained with Hoechst, and the nuclei were counted 5 days after CPT treatment. Cell survival was normalized to that in vehicle-
treated cells. The error bars represent the SD from three replicates.the aberrant function of the TONSL variants (Figure S6).
c.1615G>A (p.Glu539Lys) (P03) and c.1673G>A
(p.Arg558Gln) (P04) altered the polar interactions be-
tween amino acids. Exon 23 deletion from individuals
P01-1 and P01-2 changed the curvature of the LRR
domain significantly, and c.1989_1991del (p.664delLeu)
(P09) altered the direction of the C terminus of the helix
(Figures S6A–G). These changes deformed the overall
structures, and such changes might influence binding af-
finity between variant TONSL and its binding partners
(Figure S6). From the studies implementing in vitro cell-
based assay and in silico structural analyses, we conclude
that the identified TONSL variants compromise TONSLThe Amerifunctional activity, and that this compromise potentially
leads to human diseases.
Embryonic Lethality of the Tonsl Knock-In Mouse Model
To better understand the pathophysiology and clinical cor-
relations, we generated a CRISPR-Cas9-mediated Tonsl KI
mouse carrying a p.Arg924Trp substitution (akin to its hu-
man counterpart TONSL p.Arg934Trp variant found in in-
dividuals P01-1 and P01-2) in Tonsl (Figures 5A–C and
S7A). Heterozygous Tonslþ/Arg924Trp (HT) mice were fertile
and showed normal gross morphology. Intriguingly, no
offspring littermates (n ¼ 38) carrying the bi-allelic
p.Arg924Trp variant were obtained from heterozygouscan Journal of Human Genetics 104, 439–453, March 7, 2019 449
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Figure 5. Generation and Analysis of Homozygous Tonsl p.Arg924Trp Knock-In Mice via CRISPR-Cas9
(A) A schematic diagram showing themouse Tonsl locus and the enlarged sequences of exon 18 of tTonsl, along with the sequences of the
TonslArg924Trp allele. Blue letters in the TonslWT allele indicate a proto-spacer adjacent motif (PAM) sequence. Red letters indicate the sub-
stitution (C to T) target nucleotide in the TonslWT and the TonslArg924Trp alleles. The amino acid sequences from the TonslWT and the
TonslArg924Trp alleles are shown at the top of the nucleotide sequences. The substituted nucleotides for both synonymous and targeted
mutations are shown at the bottom of the TonslArg924Trp allele sequences by black and red asterisks (*), respectively. Forward (F) and
Reverse (R) PCR primers for genotyping are indicated.
(B) Genotyping PCR for the TonslWT and the TonslArg924Trp alleles. The upper and bottom panels show the PCR products that were
amplified from the TonslWT (115 bp) and the TonslArg924Trp (108 bp) alleles, respectively.
(C) Chromatogram displaying the sequence of the TonslWT and the TonslArg924Trp loci.
(D) Genotype distribution of offspring from heterozygous intercrosses.
(E) Gross morphology of whole embryos at stage E11.5. Tonslþ/þ and Tonslþ/Arg924Trp mouse embryos show normal development,
whereas a TonslArg924Trp/Arg924Trp embryo exhibits a growth retardation with the abnormal development of eyes and limbs.intercrosses, although their WT and HT littermates were
born in a 1:2.8 ratio (Figure 5D), suggesting that the
homozygotes were not viable. For development analysis,
we collected embryos from embryonic days 10.5 to
12.5 (E10.5E12.5) and observed a 1:1.4:0.6 ratio of450 The American Journal of Human Genetics 104, 439–453, MarchWT:HT:KI embryos (Table S4). However, all homozygous
TonslArg924Trp/Arg924Trp embryos showed early embryonic
lethality along with fetal growth restriction at around
E10.5 (Figures 5E and S7B–D). The yolk sacs of homozy-
gous TonslArg924Trp/Arg924Trp embryos lacked visible blood7, 2019
vessels and were smaller than others (Figure S7E). Consis-
tent with in vitro cell-based assays of the human TONSL
p.Arg934Trp variant, these results suggest that the Tonsl
p.Arg924Trp variant is not functional, and that the lack
of this functional protein is likely the major reason for em-
bryonic lethality. Taken together, these findings demon-
strated the physiological importance of functional Tonsl
protein in embryonic development and the pathogenic na-
ture of the TONSL p.Arg934Trp variant.Discussion
In this study, we report the identification of TONSL muta-
tions causative for SPONASTRIME dysplasia in 13 individ-
uals. We demonstrate that the endogenous TONSL protein
level in dermal fibroblast cells from the presented individ-
uals with SPONASTRIME dysplasia is significantly lower
than that in WT control cells. Furthermore, we found
that the cells from affected individuals exhibit enhanced
sensitivity to CPT, reduced DNA-damage-induced RAD51-
foci formation, and impaired replication capacity, all of
which are successfully rescued by WT-TONSL through len-
tiviral transduction. Given the importance of TONSL func-
tion in replication-fork stability during normal S phase,23 it
is reasonable to speculate that pathogenic TONSL variants
result in impaired cell proliferation, which is critical for
embryonic development and postnatal growth.24 Simi-
larly, mutations in various genes important for preventing
replication-associated DNA lesions have been identified in
individuals with growth retardation.22,24,25
In cells with a TONSL variant, we found increased phos-
phorylation of CHK1 and CHK2 (Figure 4C) in the absence
of endogenous TONSL or siRNA-mediated TONSL deple-
tion, even without treatment with genotoxic agents.
CHK1 is mainly phosphorylated by ATR (Ataxia-telangiec-
tasia and Rad3-related protein), and deleterious mutations
in the ATR (MIM:601216) gene result in Seckel syndrome
(MIM: 210600), which is characterized by microcephaly,
dwarfism, progeria, and intellectual disability.25,26 ATR re-
sponds to a many types of DNA damage, and together
with ATR-interacting protein (ATRIP), recognizes RPA
bound to ssDNA, which is often the result of a stalled repli-
cation fork.27Weobserved thatmutations inTONSLdidnot
affect the formation of RPA foci in response to CPT-induced
DNA damage in cells from individuals with SPONASTRIME
dysplasia (unpublished data), implying that TONSL func-
tionsdownstreamofATRactivation. Therefore, it is possible
to speculate that alterations in ATR, which functions up-
stream of TONSL, might lead to broader defects, whereas
loss of TONSL function might cause milder disease pheno-
types such as SPONASTRIME dysplasia. It remains un-
known why alterations in TONSL result specifically in
SPONASTRIME dysplasia and understanding the geno-
type-to-phenotype correlation requires further study.
Our KI mouse model clearly demonstrated that even a
single point mutation, p.Arg924Trp (corresponding toThe Amerip.Arg934Trp identified in human SPONASTRIME
dysplasia), causes embryonic lethality in mice. Although
this finding in the mouse model does not directly translate
to the pathogenicity of human disease, it provides evi-
dence supporting the hypothesis that the TONSL
p.Arg934Trp variant might be causative of SPONASTRIME
dysplasia, and it highlights the physiological importance
of TONSL. The homozygous p.Arg924Trp variant in mouse
Tonsl has severe developmental impact: fetal growth retar-
dation was observed at approximately E10.5 and resulted
in embryonic lethality. However, the heterozygotes surviv-
ing to adulthood showed no apparent defects. Consistent
with the in vitro cell-based assay (Figures 4B–D), these re-
sults suggest that Tonsl proteins carrying the p.Arg924Trp
variant are not functional and that the lack of this func-
tional protein is considered to be the main reason for em-
bryonic lethality in the Tonsl KO mouse (B. Lee, personal
communication) and even our KI models. However, unlike
in mice, the human TONSL p.Arg934Trp variant is found
in a subgroup of individuals with SPONASTRIME
dysplasia. The discrepancy between human and mouse
phenotypes might be due to the difference in transcript
isoforms found in humans and mice. According to the
GENCODE basic project,28 two transcripts are predicted
to be translated in humans, whereas mice only have one
transcript. Among the two transcripts in humans, the
shorter isoform lacks the domain containing the Arg934
residue, as well as the UBL and LRR domains. Whether
the shorter isoform has any function in humans has yet
to be elucidated, but the possibility that it provides partial
function for survival cannot be excluded. More research is
needed to understand the TONSL variants because the
presence of another TONSL isoform could have prevented
lethality in humans. Although further study is required if
we are to understand how the decreased function of
TONSL leads to the specific phenotype of SPONASTRIME
dysplasia, we believe that our findings increase our under-
standing of the pathogenesis of this disease.Accession Numbers
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